Program to find people with primary biliary cholangitis
Part of Digestive system clinical trials.
This trial is testing a “find patients who are missing from care” program for people with primary biliary cholangitis (PBC). It may help connect you to follow-up sooner if you’ve been hard to reach through usual clinic records.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- Your medical records show a positive AMA test, OR
- Your records show a positive ANA test for anti-gp210, OR
- Your records show a positive ANA test for anti-sp100.
- You do NOT have “overlap syndrome,” meaning PBC plus autoimmune hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a registry study that collects health information from people with primary biliary cholangitis (PBC), a rare liver disease where the immune system damages bile ducts. By joining, you help researchers better understand PBC and improve care for patients with this condition.
This study follows adults with primary biliary cholangitis (a long-term liver and bile duct condition). It may help doctors better understand the disease in different people, including those identified by specific blood antibody tests.
This study creates a national registry (database) of adults in Italy living with primary biliary cholangitis (PBC). Being included can help doctors better understand the condition and improve future care.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This trial tracks how well the combination of ursodiol and seladelpar works in people with primary biliary cholangitis (PBC), a liver disease. It aims to see if this treatment helps control symptoms and liver function.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.